MISSISSAUGA, Ontario, Oct. 6 /PRNewswire/ — Dr. Yahia Gawad,
CEO of CardioGenics Inc. (OTC Bulletin Board:
CGNH), has authored a cover story for this month’s Medical
Device & Diagnostic Industry Magazine (MD+DI) which
addresses improvements in diagnostic times using
point-of-care technology. In the article, titled “Improving
Diagnosis Times with New Point-of-Care Technology,” Dr. Gawad
reviews the in-vitro diagnostics market and the growth of
point-of-care testing.
In addition to reviewing other point-of-care devices, Dr. Gawad
describes the operation of the QL Care Analyzer™,
CardioGenics’ point-of-care immunoassay platform that will allow a
heart attack diagnosis to be made in as little as 15 minutes vs.
the national average of 2.8 hours required for test results from a
central lab. CardioGenics expects to submit to the FDA a 510K
application for the QL Care Analyzer™ (and its first cardiac
test, Troponin-I) during Q1 2011 and to have both commercialized by
Q2 2011.
The article can be accessed online at:
http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology
About Medical Device & Diagnostics Industry
Medical Device & Diagnostic
Industryis a leading monthly magazine written
exclusively for original equipment manufacturers of medical devices
and in vitro diagnostic products. The goal of MD&DI
is to help industry professionals develop, design, and
manufacture medical products that comply with complex and demanding
regulations and market requirements. MD&DI is
published 12 times each year, along with two additional issues of
its Guide to Outsourcing supplement.
About CardioGenics
‘/>”/>
